Method of obtaining derivatives of imidazole or their salts with acids

专利摘要:
The invention relates to derivatives; Imidazole, in particular compounds of the formula Xx - KG .OP2 (-0) n-CH, R, ab N where R, and R, H, lower alkyl; R is lower alkyl; or 1; And - the residue of the formula: -O-CH -O; (0) -CRY or -CR, R5-C (N-ORd) -CR6R, where R is lower alkyl; or lower alkyl, or their salts with acids, which have the ability to inhibit the formation of ST and absorption of gastric acid. To increase this activity, new compounds were obtained. Their synthesis is carried out from compounds of the formulas, Y-CH -fVPs (IO, N where R, -R are indicated above; Y and Y - one means mercapto group, and the other - halo, and produce the desired product with or oxidized and isolate The desired product is present in free form or as an acid salt. Tests show that compounds (I) are less toxic and more active than known compounds, for example, 6- (5-metip-B1-pyridylmethyl) thio-5H-1,3- Dioxolo 4,5-f benzimidazole Table 2: FROM 00 05 S 4; N3
公开号:SU1362402A3
申请号:SU853884504
申请日:1985-04-18
公开日:1987-12-23
发明作者:Фишли Альберт；Крассо Анна；Рамуц Хенри；Сенте Андре
申请人:Ф.Хоффманн-Ля Рош Унд Ко Аг (Фирма)；
IPC主号:

专利说明:


CH
The invention relates to a process for the preparation of new imidazole derivatives with valuable pharmacodynamic properties, since, with non-significant toxicity, they inhibit the formation of ulcers and the secretion of gastric acid.
The purpose of the invention is a method for producing new compounds that have a biological activity that is superior to the known ones, which have the same type of activity.
Example.
To a solution of 24 g (0.22 mol) of 2.3-15 dimethylpnridine in 100 ml of methylene chloride, while cooling with ice, a solution of 46.6 g (0.27 mol) of m-chloroperbenzoic acid in an TOO of ml of methylene chloride is added. The reaction 20 mixture is heated for 2 hours to reflux and concentrated on a rotary evaporator. The residue is chromatographed on silica gel using just 4-methoxy-2,3-dimethylpyridine-1-oxide with m.p. 80-83 C.
A solution of 500 mg (3.26 mmol) of 4-methoxy-2,3-dimethylpyridine-1-oxide in 20 ml of 1,2-dichloroethane is heated to reflux and 8.3 g of trichloroacetic acid chloride is added. After 35 minutes, the reaction mixture was poured onto ice, after which a solution of 10% sodium carbonate was added, extracted with methylene chloride, the solution of methylene chloride was dried and concentrated. The 2-chloromethyl-3-methyl-4-methoxypyridine thus obtained is directly processed as a crude product.
To a solution of 690 mg of crude 2-chloromethyl-3-methyl-4-methoxypyridine and 400 mg of 5.7 dihydro-2-mercapto-5.5, 7.7-tetramethylindeno 5,6-d imidazol-6 (1H) - it in 1 ml of absolute acetone is added 1, 9 g of finely ground
Acetic ether / methylene chloride is 5 potassium carbonate, followed by stirring (3: 1) as eluent, and a single chromatographic method with an average pressure caused by nitrogen gas is used. After recrystallization from ether, 2,3-dime- 30 methylene / ethyl acetate (10: 1) is obtained in
18 hours at room temperature under argon. After concentrating the mixture in vacuo, the residue is chromatographed on silica gel with chloride
tilpyridin-1-oxide, so pl. 56 s (flash chromatography).
To a solution of 183 mg (1.49 mmol) of 2,3-dimethylpyridine-1-oxide in 0.6 ml of concentrated sulfuric acid, 0.2 ml of 65% nitric acid (, 4) is added with ice cooling. The reaction mixture is stirred during the day (90 ° C), extracted into a mixture of ice and sodium carbonate, then taken out with methylene chloride, the methylene chloride phase is dried and evaporated. The residue crystallizes from ethanol / n-pentane and is a 2,3-dimethyl-4-nitropyridine-1-oxide with m.p. 99-102 ° C.
To a solution of 2.5 g (0.015 mol) of 2-, 3-dnmethyl-4-nitropyridine-1-oxide in 50 ml of absolute methanol was added 0.883 g of sodium methoxide, then stirred for two days in an argon atmosphere at room temperature. The reaction mixture is concentrated, the residue is taken up in methylene chloride and a saturated solution of sodium chloride. The methylene chloride phase is dried and evaporated. Crystallization from methylene chloride / ether gives the residue, and
35
40
as eluent, using the method of single chromatography with an average pressure caused by nitrogen gas. Recrystallization from ethyl acetate / ether gives 5,7-dihydro-2-g (4-methoxy-3-methyl-2-pyridyl) methyl thio-5,5,7,7-tetramethylindeno 5,6-d imidazole-6 (1H) -one with m.p. 218-220 ° C.
Example2. To a solution, 6 g (0.015 mol) of 5,7-dihydro-2 - ((4-methoxy-3-methyl-2-pyridyl) methyl thio - 5,5,7,7-tetramethylindeno 5,6-d - im- .d azole-6 d H 9-it in 90 ml of absolute methylene chloride is added to the atmosphere of the sphere of argon at -40 to -50 ° C for 10 minutes a solution of 3.3 g (0.019 mol) m -chloroperbenzoic acid in 50 ml of absolute methylene chloride. The solution is then stirred for an additional 20 minutes, extracted with a 10% sodium carbonate solution, dried and evaporated with a constant replacement of methylene chloride with ethyl acetate. At the same time, 5,7-dihydr is crystallized o-2- (4-methoxy- 3-methyl-2-pyridsh1) methyl} sulfinyl - 5,5,7,7-tetrametesh1indo G5,6-d imidazole-6 (1H) -one, so-called by doping .
192-194 ° С (with 4-methoxy-2,3-dimethylpyridine-1-oxide, with a melting point of 80-83 C.
A solution of 500 mg (3.26 mmol) of 4-methoxy-2,3-dimethylpyridine-1-oxide in 20 ml of 1,2-dichloroethane is heated to reflux and 8.3 g of trichloroacetic acid chloride is added. After 35 minutes, the reaction mixture was poured onto ice, after which a solution of 10% sodium carbonate was added, extracted with methylene chloride, the solution of methylene chloride was dried and concentrated. The 2-chloromethyl-3-methyl-4-methoxypyridine thus obtained is directly processed as a crude product.
To a solution of 690 mg of crude 2-chloromethyl-3-methyl-4-methoxypyridine and 400 mg of 5.7 dihydro-2-mercapto-5.5, 7.7-tetramethylindeno 5,6-d imidazol-6 (1H) - it in 1 ml of absolute acetone is added 1, 9 g of finely ground
potassium carbonate, then mixed with methylene / ethyl acetate (10: 1) in
18 hours at room temperature under argon. After concentrating the mixture in vacuo, the residue is chromatographed on silica gel with chloride
potassium carbonate, then mixed with methylene / ethyl acetate (10: 1) in
as eluent, using the method of single chromatography with an average pressure caused by nitrogen gas. After recrystallization from ethyl acetate / ether, 5,7-dihydro-2-G (4-methoxy-3-methyl-2-pyridyl) methyl is obtained. thio-5,5,7,7-tetramethylindeno 5,6-d imidazol-6 (1H) -one with so pl. 218-220 ° C.
Example2. To a solution, 6 g (0.015 mol) of 5,7-dihydro-2 - ((4-methoxy-3-methyl-2-pyridyl) methyl thio - 5,5,7,7-tetramethylindeno 5,6-d -imidazole-6 d H 9-it in 90 ml of absolute methylene chloride is added under argon at a temperature of from -40 to -50 ° C for 10 minutes a solution of 3.3 g (0.019 mol) m-chloroperbenzoic acid in 50 ml of absolute methylene chloride. The solution is then stirred for an additional 20 minutes, extracted with 10% sodium carbonate solution, dried and evaporated, with constant replacement of methylene chloride with ethyl acetate, and 5,7-dihydro-2- (4- m toxins 3-methyl-2-piridsh1) sulfinyl methyl} - 5,5,7,7-tetrametsh1indeno G5,6-d imidazol-6 (1H) -one, m.p. decomposition).
192-194 ° C (c. EXAMPLEZ. To 500 ml of 5% aqueous solution of methyl lithium in ether is added dropwise at room temperature under argon atmosphere 1200 ml of ether, then 35.6 g of 3.5 lutidna (3.5- dimethylpyridine) and another 400 ml of toluene. The ether is completely distilled off, after which the solution is stirred for 4 hours at 100 ° C, Cooling with methanol / ice, ice is added in portions until the temperature increases. The toluene phase is separated from the precipitated solid and 66 ml of semi-concentrated hydrochloric acid are recovered. The separated aqueous phase is treated with 3N sodium hydroxide solution while cooling to t to a pH of 10, extracted twice with 300 ml of ether. The ether extracts are dried with sodium sulfate and evaporated. The residue is distilled off in vacuo at 20 mm (72-74 ° C) to give 2,3,5-colidine (-2.3 , 5-trimethylpyridine) with a purity of 99.15% (gas chromatography).
To 246.4 g of 2,3,5-collidinium and 2400 ml of acetic ice, 420 ml of 30% hydrogen peroxide are added dropwise at room temperature. The solution is stirred overnight at 80 ° C. Then the reaction mixture is cooled to 40 seconds, and 420 ml 30% is added again. hydrogen peroxide and continue to heat during the day to 80 ° C. It is evaporated in vacuo, the residue is dissolved in 300 ml of water, the solution is cooled with a concentrated solution of caustic soda and brought to the basic state, saturated with sodium chloride and extracted three times with methylene chloride (1 l). The organic phases are dried with sodium sulfate and evaporated in a vacuum. The residue is crystallized from ether / petroleum ether to give 2,3,5-trimethylpyridine-α-oxide with m.p. .- -.
: To 210 ml of concentrated sulfuric acid is added dropwise with cooling 65 ml of fuming nitric acid (, 5). Then, at 0-5 ° C, 96.5 g of 2,3,5-trimethylpyridine-1-oxide are added in portions, the mixture is stirred for 1 hour at room temperature, then heated for 3 hours to 90 ° C and kept overnight at this temperature. After cooling, the solution is poured onto 1.5 kg of ice, adjusted to pH 3 with concentrated sodium hydroxide solution and extracted three times with methylene chloride (500 ml). Connect
Q. s o
5 o o
five,
0 g
five
The organic phases are washed with 1 l of water, dried over sodium sulfate and evaporated in vacuo. The residue after crystallization from ether / petroleum ether gives 2,3,5-trimethyl-4-nitropyridine-1-oxide with m.p. 76-78 s.
22.6 g of sodium are dissolved in 4 L of methanol under argon. Then 120 g of 2,3,5-trimetsh-1-4-nitropyridine-1-oxide are added in portions and the solution is heated to reflux overnight. Cool, using 5 n. the hydrogen chloride in ethyl acetate was adjusted to pH 7, then the mixture was evaporated in vacuo. The residue is dissolved in 1.5 l of methylene chloride, the solution is filtered through silica gel, followed by washing with the last 0.5 l of methylene chloride, the combined filtrates are evaporated in vacuo and crystallization of the residue from petroleum ether gives 4-methoxy-2,3-5- trimethylpyridine-1- oxide with so pl. 48-50 C.
To a solution of 81.5 g of 4-methoxy-2,3, 5-trimethylpyridine-1-oxide in 290 ml of chloroform, 215 ml of acetic anhydride is added dropwise at room temperature. After heating to reflux for 4 hours, the solution is evaporated, the residue is dissolved in 500 ml of toluene, and the flask is evaporated. The residue is dissolved in 500 ml of ethyl acetate and shaken three times with 250 ml of saturated sodium bicarbonate solution. The organic phase is dried over sodium sulfate and evaporated in vacuo. The product remaining as a residue, is subjected to chromatography on 400 g of silica gel with ether. (4-methoxy-3,5-dimethyl-2-pyridyl) methyl acetate is obtained as; oils.
94.9 g of (4-methoxy-3,5-dimesh1-2-pyridyl) methyl acetate is dissolved in 570 ml of ethanol. Then, 285 ml of 3N is added dropwise with the drop. sodium hydroxide solution and the mixture is stirred for 3 hours. at room temperature. Ethanol; removed in vacuo and the resulting aqueous solution is extracted three times with 300 ml; methylene chloride. The organic residues are dried with sodium sulfate and evaporated in vacuo. The residue after crystallization from petroleum ether gives 4-methoxy-3, 5-dimethyl-2-pyridyl-methaiol with so pl. 49-51 C.
o ° with
75.8 g of 4-methoxy 3,5-dimethyl-2-pyrCl1 is added dropwise to 38 ml of thion chloride in 400 ml of methylene chloride, and methyl methanol dissolved in 200 ml of methylene chloride. After stirring for 16 hours at room temperature, 1800 ml of ether are added dropwise while cooling and the mixture is kept stirring for 2 hours at room temperature. The precipitated crystals are filtered off and suction with ether. Get 2- (chloromethyl) -4-methoxy-3,5-dimethylpyridine hydrochloride with t, mp TZO-TZT C,
18.0 g (69.2 mmol) of 5,7-dihydro-2-mercapto-5,5,7,7-tetramethylindeno 5,6-d imidazole-6 (1H) -one is weighed into 400 ml of alcohol and while cooling 15.6 g (70.2 mmol) of 2-chloromethyl-5-methoxy-3,5-dimethylpyridine hydrochloride are added with ice. Then a solution of 5.6 g of sodium hydroxide in 150 ml of water is added dropwise, the mixture is
Overnight, the mixture is heated to reflux temperature, followed by evaporation to dryness in vacuo. The residue is dissolved in 1000 ml of methylene chloride, the solution is first washed with 500 ml of 1.5 N sodium hydroxide solution, then three times with water (up to 500 ml), dried with sodium sulfate and evaporated in vacuo. The crude product is purified on 300 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluent. After crystallization from methylene chloride / petroleum ether, 5,7-dihydro-2- (4-methoxy-, 5-dimethyl-2-pyridyl) methyl thio-5,5,7,7-tetramethylindeno 5,6-d are obtained. imidazole-6 (1H) -one with t, pl, 166-168 ° C,
2.6 g of 5,7-dihydro-2 - {(4-methoxy-3,5-dimethyl-2-pyridyl) methyl thio - 5,5,7,7-tetramethylindo 5, (-d imidazol-6 ( The 1H) -one is dissolved in 50 MP of hot methanol and together with 50 mp of 2N, the solution of hydrogen chloride in methanol is heated to reflux for 10 minutes. After evaporation in vacuum, it is recrystallized from ether to give 5,7-dihydro-2- hydrochloride ( 4-methoxy-3,5-dimethyl. After concentration of the eluate in Kuum, 5,7-dihydro-2-GG is crystallized (4-methoxy-3,5-dimethyl-2-pyr
h L 1 T
dil) -methyl} -thio) | -5,5, 7,7-tetramethyl 2 d-5,6-d imidazol-6 (1H) -on-oxime, t, mp, 233-235 C,
Primer3, 4.2 g of sodium is dissolved in 780 ml of ethanol under argon atmosphere. Portions are then added.
35 22.3 g of 2,3,5-trimetsh-1-4-nitropyridium 1-oxide and the solution is heated to reflux overnight. Using 5 n of hydrogen chloride in ethyl acetate while cooling the vents
40 dt to pH 7 and the mixture is evaporated in vacuo. The residue is dissolved in 0.5 l of methylene chloride, the solvent is filtered through silica gel, which is additionally washed with 200 ml of chloride.
45 of methylene, the combined filtrates are evaporated in vacuo and the residue is crystallized from petroleum extract. I get 4-ETOXI-2,3,5-trimethylpyridin-1-ok seed with t, pc, 59-b1 ° C,
50 To a solution of 31.3 g of 4-ethoxy-2,3,5 trimethylpyridine-1-oxide in 100 ml of chloroform, 75 ml of acetic anhydride are added dropwise at room temperature. After heating to that, 2-pyridyl) -methyl thio -5,5,7,7-tetra-gg of reflux distilled for 16 h.
I. . J f f f
methylindeno 5,6-dJ imidazole-6 (1H) -one with t, pl. 1b5-170 ° C,
Example4. 8, 3g 5,7-dihydro-2- (4-meth hydroxy-3,5-dimethyl-2-pyridyl)
the solution is isolated, the residue is dissolved in 100 ml of toluene and again injected. The residue is dissolved in 250 ml of acetic acid ester, then three times
ten

25
15

24026
methyl -Toj-5,5,7,7-tetramethylindeno. 5,6-d imidazole-6 (1H) -one is dissolved in 1000 ml of methylene chloride and cooled in an ice / methanol bath to -10 ° C, then in 4.3 ml of recrystallized methylene chloride / m-chloroperbenzoic acid petroleum ether are introduced over 25 minutes. Continue to mix at -10 ° C for 45 minutes, then the solution is poured into a mixture of 100 ml 2 n. sodium carbonate solution and ice. The aqueous phase is extracted twice. 300 ml of methylene chloride. The combined organic phases are washed with 200 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at 35 ° C to a volume of 150 ml. After the addition of petroleum ether, 5,7-DIHIDRO-2- {(4-methoxy-3,5-dimethyl-2-pyridyl) methyl sul- crystallizes. Final-5,5,7,7-tetrametsh1indo 5,6-1-imidazole-6 (1H) -one with t, pl. 192-194 with,
After concentrating the eluate in vacuo, 5,7-dihydro-2-GG (4-methoxy-3,5-dimethyl-2-pyrich L 1 T) is crystallized
dil) -methyl} -thio) | -5,5, 7,7-tetramethyl-2d, 5,6-d imidazole-6 (1H) -on-oxime, t, mp, 233-235 C,
20
Example 3, 4.2 g of sodium is dissolved in 780 ml of ethanol under argon atmosphere. Portions are then added.
35 22.3 g of 2,3,5-trimetsh-1-4-nitropyridine-1-oxide and the solution is heated to reflux overnight. With 5 n, hydrogen chloride in ethyl acetate, with cooling, is adjusted to 40 d to pH 7 and the mixture evaporated in vacuo. The residue is dissolved in 0.5 l of methylene chloride, the solution is filtered through silica gel, which is additionally washed with 200 ml of chloride
45 of methylene, the combined filtrates are evaporated in vacuo and the residue is crystallized from petroleum efkra. Get 4-ETOXI-2,3,5-trimethylpyridine-1-oxide with t, units, 59-B1 ° C,
50 To a solution of 31.3 g of 4-ethoxy-2,3,5-trimethylpyridine-1-oxide in 100 ml of chloroform at room temperature is added dropwise 75 mp of acetic anhydride. After heating to those.
gg of reflux distilled within 16 h
the solution is isolated, the residue is dissolved in 100 ml of toluene, and again injected. The residue is dissolved in 250 ml of ethyl acetate, followed by three times
Shake with 100 ml of saturated sodium bicarbonate solution. The organic phase is dried with sodium sulfate and evaporated in vacuo. The crude product is chromatographed over 170 g of silica gel in ether. (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl acetate is obtained in the form of an oil.
Example 6. 7.3 g of 5,7-dihydro-, 2- (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl 3, 5,7,7-tetramethylindeno 5,6-d} imidazole-6 ( The 1H) -one is dissolved in 3 750 ml of methylene chloride and cooled in an ice / methanol bath to -10 ° C. Then, within 5 minutes, add I 5
3.7 g of recrystallized from
32.9. (4-ethoxy-3,5-dimethyl-2-pi-methylene chloride / petroleum ether) -methyl acetate are dissolved in 190 ml of ethanol. Then added dropwise at 95 ml 3 n. caustic soda solution and continue to stir for 3 hours at room temperature. The ethanol is then removed in vacuo and the remaining aqueous solution of extras. Thrice three times with 200 ml of methylene chloride. The organic extracts are dried with sodium sulfate and evaporated in vacuo. The residue after crystallization from petroleum ether gives 4-ethoxy-3,5-dimethyl-2-pyridylmethanol with m.p. 58-59 with.
K-10 ml of thionyl chloride in 220 ml of methylene chloride is added, dropwise at 0 ° C, 21.0 g of 4-ethoxy-3.5 dimesh1-2-pyridine methanol dissolved in 110 ml of methylene chloride. After stirring for 16 hours at room temperature, 890 ml of ether are added dropwise with cooling and the mixture is stirred for 2 hours at room temperature. The crystals that have entered are filtered through suction and washed with ether. 2-chloromesh-1-4-ethoxy-3,5-rimethylpyridine hydrochloride is obtained with m.p. 156-158 C.
15
20
ra m-chloroperbenzoic acid. Continue to stir the solution at this temperature for 75 minutes, then pour the latter into the mixture 100 ml 2 n. sodium carbonate solution and ice. The aqueous phase is extracted twice with 300 ml of methylene chloride. The combined organic phases are washed three times with 200 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at 35 ° C to a volume of 120 ml. After crystallization by adding petroleum ether: 5,7-dihydro-2-25 (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl sulfinyl-5,5,7,7-tetramethylindeno 5,6 -dl imidazole-6 (1 H) -one, so pl. 185-187 ° C.
Example 7. To 321.5 g of 2.5-luti-30dine (2,5-dimethylpyridine) in 1800 ml of acetic ice, 400 ml of 30% hydrogen peroxide are added dropwise at room temperature; The solution is stirred overnight at 80 ° C, then cooled to 4 ° C, 400 ml of 30% hydrogen peroxide are added again and heated to 80 ° C overnight. After evaporation in vacuo, the residue is dissolved in 300 ml of water. The solution is brought to a basic state while cooling with a concentrated solution of sodium hydroxide, saturated with sodium chloride and extracted three times with 1 liter of methylene chloride. Organic
35
Example 7. To 321.5 g of 2.5-luti-30dine (2,5-dimethylpyridine) in 1800 ml of acetic ice, 400 ml of 30% hydrogen peroxide are added dropwise at room temperature; The solution is stirred overnight at 80 ° C, then cooled to 4 ° C, 400 ml of 30% hydrogen peroxide are added again and heated to 80 ° C overnight. After evaporation in vacuo, the residue is dissolved in 300 ml of water. The solution is brought to a basic state while cooling with a concentrated solution of sodium hydroxide, saturated with sodium chloride and extracted three times with 1 liter of methylene chloride. Organic
7.8 g (30 mmol) of 5,7-dihydro-2-mer-40 capto-5,5,7,7-tetramethylenide 5, 6-d imidazole-6- (1H) -he is weighed in 200 ml of alcohol and under ice cooling, 7.1 g (30 mmol) of 2-chloromethyl-4-ethoxy-3.5 dimethylpyri-45 P hydrochloride is added and dried over sodium sulfate. The solution is then added dropwise and evaporated in vacuo. 2.5-2.4 g of sodium hydroxide are obtained in 100 ml of hydroxypyridine-1-oxide as an oil, dy, heated to overnight to 840 ml of concentrated sulfuric reflux followed by evaporation to dryness and vacuum. The crude product is purified on 150 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluent. Crystallization from methylene chloride / petroleum ether gives 5,7-dihydro-2- (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl, 5,7,7-tetramethylindeno G5,6-d3 imidazol-6 (1H) -one with m.p. 179-180 C.
acids are added dropwise while cooling with 260 ml of fuming nitric acid (, 5). Then at 0-5 ° C, 348.2 g of 2,5-dimethylpyridine-1-oxide are added in portions. The mixture is stirred for 1 h at
55
at room temperature, then heated to 90 ° C for 3 hours, held overnight at this temperature and, after cooling, poured onto 6 kg of ice. The concentrated sodium hydroxide solution is adjusted to pH 3 and
t- -
13624028
Example 6. 7.3 g of 5,7-dihydro-, 2- (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl 3, 5,7,7-tetramethylindeno 5,6-d} imidazole-6 ( The 1H) -one is dissolved in 3 750 ml of methylene chloride and cooled in an ice / methanol bath to -10 ° C. Then, within 5 minutes, add I 5
3.7 g of recrystallized from
methylene chloride / petroleum ether
ra m-chloroperbenzoic acid. Continue to stir the solution at this temperature for 75 minutes, then pour the latter into the mixture 100 ml 2 n. sodium carbonate solution and ice. The aqueous phase is extracted twice with 300 ml of methylene chloride. The combined organic phases are washed three times with 200 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at 35 ° C to a volume of 120 ml. After crystallization by adding petroleum ether, 5,7-dihydro-2- (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl sulfinyl-5,5,7,7-tetramethylindeno 5,6- dl imidazole-6 (1 H) -one, so pl. 185-187 ° C.
Example 7. To 321.5 g of 2,5-lutidine (2,5-dimethylpyridine) in 1800 ml of acetic ice at room temperature, 400 ml of 30% hydrogen peroxide are added dropwise; The solution is stirred overnight at 80 ° C, then cooled to 4 ° C, 400 ml of 30% hydrogen peroxide are added again and heated to 80 ° C overnight. After evaporation in vacuo, the residue is dissolved in 300 ml of water. The solution is brought to a basic state while cooling with a concentrated solution of sodium hydroxide, saturated with sodium chloride and extracted three times with 1 liter of methylene chloride. Organic
 P is dried with sodium sulfate and evaporated in vacuo. 2.5-dimethylpyridin-1-oxide is obtained in the form of an oil, K 840 ml of concentrated sulfuric
40 45 P dried over sodium sulfate and evaporated in vacuo. 2.5-dimethylpyridin-1-oxide is obtained in the form of an oil, K 840 ml of concentrated sulfuric
acids are added dropwise while cooling with 260 ml of fuming nitric acid (, 5). Then at 0-5 ° C, 348.2 g of 2,5-dimethylpyridine-1-oxide are added in portions. The mixture is stirred for 1 h at
40 45 P dried over sodium sulfate and evaporated in vacuo. 2.5-dimethylpyridin-1-oxide is obtained in the form of an oil, K 840 ml of concentrated sulfuric
55
at room temperature, then heated to 90 ° C for 3 hours, held overnight at this temperature and, after cooling, poured onto 6 kg of ice. The concentrated sodium hydroxide solution is adjusted to pH 3 and
extracted three times with 2 l of methylene chloride. The combined organic phases are washed with 4 liters of water, dried with sodium sulfate and evaporated in vacuo. The residue after crystallization from methylene chloride / petroleum ether gives 2,5-dimethyl-4-nitropyridine-1-oxide with so pl. 142-144 s.
12.2 g of sodium under argon are dissolved in 2 liters of methanol, then 60 g of 2,5-dimethyl-4-nitropyridine-1-oxide is added in portions and the solution is heated to reflux overnight. With 5 n. hydrochloric acid in ethyl acetate was cooled to pH 7 with cooling and the mixture was evaporated in vacuo. The residue is dissolved in 1 L of methylene chloride, the solution is filtered on silica gel, which is additionally washed with 0.4 L of methylene chloride and the combined filtrates are evaporated in vacuo. After crystallization of the residue from methylene chloride / petroleum ether, 4-methoxy-2,5-dimethylpyridine-1-oxide with m.p. 99-101 ° C.
To a solution of 19.9 g of 4-methoxy-2,5-dimethylpyridine-1-oxide in 75 ml of chloroform, 55 ml of acetic anhydride is added dropwise at room temperature. After heating to 55 ml of acetic anhydride. After heating to reflux for 2 hours, the solution is evaporated, the residue is dissolved in 100 ml of toluene and reconstituted again. The residue was dissolved in 100 ml of ethyl acetate, and the solution was shaken three times with 50 ml of saturated sodium bicarbonate solution. The organic phase is dried on sodium sulfate and evaporated in vacuo. The crude product is chromatographed on silica gel (100 g) with ether to give (4-methoxy-5-methyl-2-pyridyl) methyl acetate as an oil.
47.8 g of (4-methoxy-5-metsh1-2-pyridyl) methyl acetate are dissolved in 330 ml of ethanol. Then, 165 ml of 3 N sodium hydroxide solution is added dropwise at the reaction with OC and the mixture is stirred for 3 hours at room temperature. The ethanol is then removed in vacuo, after which the remaining aqueous solution is extracted three times with 250 ml of methylene chloride. The organic extracts are dried with sodium sulfate and evaporated in vacuo. After crystallization of the residue from petroleum ether, 4-methoxy is obtained.
five
5-methyl-2-pyridylmethanol with m.p. , 101 103 ° C.
. To 17 ml of thionyl chloride in 360 ml of methylene chloride is added dropwise with 28.1 g of 4-methoxy-5-methyl-2-pyridine-methanol, dissolved in 180 ml of methylene chloride. After stirring for 16 hours at room temperature, 1400 ml of ether is added dropwise with cooling and the mixture is stirred for 2 hours at room temperature. The precipitated crystals are filtered under suction and washed with ether. Hydrochloride is obtained
2- (chloromethyl) -4-methoxy-5-methylpyri- so pl. 149-151 ° C. g (300 mmol) 5,7-DIGIDRO-25
dina with
7, "mercapto-5,5,7,7-tetramethylindeno
0 5,6-1-imidazole-6 (1H) -one is weighed into 200 MP of alcohol and 6.3 g (30 mm) of 2-chloromethyl-4-methoxy-5-methylpyridine hydrochloride is added with ice cooling. Then add by
5 drops of a solution of 2.4 g of sodium hydroxide in 100 ml of water are heated to reflux overnight and then evaporated to dryness in vacuo. The residue is dissolved in 500 ml
0 methylene chloride. The solution is first washed with 250 ml of 1.5N. sodium hydroxide solution, then three times with water (250 ml each), dried with sodium sulfate and evaporated in vacuo. The crude product is purified on 150 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluant. After crystallization from methylene chloride / petroleum ether, 5,7-dihydro-2- | (4-methoxy-5-methyl-2-pyridyl) methyl; thio} -5,5,7,7-tetramethylindeno 5,6-d imidazol-6 (1 H) -one with so pl. 204-205 s.
PRI me R 8. 9.5 g of 5,7-dihydro-2- (4-methoxy-5-methyl-2-pyridsh1) - methyl 3, 5,7,7-tetramethylindeno 5, b-e imidazole- 6 (1H) -one is dissolved in 1000 ml of methylene chloride and cooled to an ice / methanol bath. 4.7 g of m-chloroperbenzoic acid recrystallized from methylene chloride / petroleum ether are then added over 30 minutes. Continue to stir the solution for another 2 h at -10 ° C, then the solution is poured into a mixture of 150 ml of 2N. sodium carbonate solution and ice. The aqueous phase is drawn twice. 300 ml of chloride
0
111
methylene. The combined organic phases are washed three times with 200 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at 35 ° C to a volume of 150 ml. Crystallization after addition of petroleum ether gives 5,7-dihydro-2 (4-methoxy -5-methyl. 2-pyridyl) methyl sulfinsht -5,5,7,7-tetramethylindeno 5,6-d Zimidazol-6 (1H) -one, m.p. 191-193 ° C ..



25
Example 9, 13.5 g of sodium is dissolved in 2300 MP of ethanol in an argon atmosphere. Then 60 g of 1B 2,5-dimethyl-4-nitropyridine-1-oxide is added in portions and heated to reflux overnight. Using 5 n of hydrogen chloride in ethyl acetate, the mixture is cooled to pH 7 after cooling. after which the mixture is evaporated in vacuo, the solvent is dissolved in 1 liter of methylene chloride, the solution is filtered through silica gel, which is additionally washed with 500 ml of methylene chloride, and the combined filtrates are evaporated in vacuo. The crude product is chromatographed on 300 g of silica gel using methylene chloride / methanol (95: 5) as eluent. After crystallization from ether / petroleum ether, 4-ethoxy-2,5-dimethylpyridine-1-oxide is obtained with mp., 65-67 ° C,
To a solution of 7.8 g of 4-ztoxy-2,5-dimethylpyridin-1-oxide in 30 ml of chloroform, 20 ml of acetic anhydride is added dropwise at room temperature. After heating to reflux for 3 hours, the solution is evaporated, the residue is dissolved in 50 ml of toluene and again evaporated. The residue was dissolved in 50 ml of ethyl acetate, after which the solution was shaken three times with 20 ml of saturated solution.
35
40
2-pyridylmethanol dissolved in 30 ml of methylene chloride. After stirring for 16 hours at room temperature, 400 ml of ether are added dropwise with cooling and the mixture is stirred for 2 hours at room temperature. Inserted crystals are filtered under suction and washed with ether. 2-chloromethyl-4-ethoxy-5-methypyridine hydrochloride is obtained with m.p. 144-146 ° C.
6.1 g (23.4 mmol) of 5,7-dihydro-2-mercapto-5,5,7,7-tetramethylindeno 5,6-d imidazole-6 (1H) -one are weighed into 100 ml of alcohol and added when cooled with ice, 5.2 g (23.4 mmol) of 2-chloromethyl-4-ethoxy-5-methylpyridine hydrochloride. Then a solution of 1.9 g of sodium hydroxide in 50 ml of water is added dropwise, the mixture is heated to reflux overnight and evaporated to dryness in vacuo. The residue is dissolved in 300 ml of methylene chloride. The solution is washed first with 200 ml of 1.5 N sodium hydroxide solution, then three times with 200 ml of water, dried with sodium sulfate and evaporated in vacuo. The crude product is purified on 120 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluent. After crystallization from methylene chloride / petroleum ether, 2- {(ethoxy-5-methyl-2-pyridyl) methyl thio | -5,7-dihydro-5,5 is obtained
sodium bicarbonate blend. The organic 45.7,7-tetramethylindenor, 6-11 imidazole phase is dried on sodium sulfate and evaporated in vacuo. With product, it is chromatographed on 50 g of silica gel using zephre, and (4-ethoxy-5-methyl-2-pyridyl) methyl acetate is obtained in the form of oil.
7.4 g of (4-ethoxy-5-methyl-2-pyridyl) methyl acetate are dissolved in 46 ml of ethanol. Then, 23 MP 3 n is added dropwise. sodium hydroxide solution and continue to stir the mixture for 3 hours at room temperature. The ethanol is then removed under vacuum and the remaining aqueous solution is extracted three times with 100 ml.
402
12
methylene chloride. The organic extracts are dried with sodium sulfate and evaporated in vacuo. After crystallization of the residue from petroleum ether, 4-ethoxy-5-methyl-2-pyridylmethanol is obtained with mp. 99-101 ° C,
, To 2.4 ml of thionyl chloride in 60 ml of methylene chloride is added dropwise in drops of 4.7 g of k-ethoxy-5-methyl5
In 0
0
five
0
2-pyridylmethanol dissolved in 30 ml of methylene chloride. After stirring for 16 hours at room temperature, 400 ml of ether are added dropwise with cooling and the mixture is stirred for 2 hours at room temperature. Inserted crystals are filtered under suction and washed with ether. 2-chloromethyl-4-ethoxy-5-methypyridine hydrochloride is obtained with m.p. 144-146 ° C.
6.1 g (23.4 mmol) of 5,7-dihydro-2-mercapto-5,5,7,7-tetramethylindeno 5,6-d imidazole-6 (1H) -one are weighed into 100 ml of alcohol and added under ice cooling, 5.2 g (23.4 mmol) of 2-chloromethyl-4-ethoxy-5-methylpyridine hydrochloride. Then a solution of 1.9 g of sodium hydroxide in 50 ml of water is added dropwise, the mixture is heated to reflux overnight and evaporated to dryness in vacuo. The residue is dissolved in 300 ml of methylene chloride. The solution is washed first with 200 ml of 1.5 N sodium hydroxide solution, then three times with 200 ml of water, dried with sodium sulfate and evaporated in vacuo. The crude product is purified on 120 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluent. After crystallization from methylene chloride / petroleum ether, 2- {(ethoxy-5-methyl-2-pyridyl) methyl thio | -5,7-dihydro-5.5, is obtained,
5 7,7-tetramethylindenor, 6-11 imidazole 7, 7-tetramethylindenor, 6 11 imidazole
6 (1H) -one with m.p. 187-189 ° C; Example 9 10. 6 g 2- {(4-methoxy-5-methyl-2-pyridyl) methyl thio-5,6-dihydro-5,5,7, 7-tetramethylindeno 5,6-dJ imidazole-6 (1H) -one is dissolved in 300 ml of methylene chloride and cooled in a bath with dry ice / acetone to -30 ° C. Then within 4.0 hours 4.0 g of m-chloroperbenzoic acid recrystallized from methylene chloride / petroleum ether are introduced. Continue to stir the solution for 2 hours at -10 ° C, then pour it into a mixture of 100 ml of 2N sodium carbonate solution,.
ratri 35 ° C to
131362402
and ice. The aqueous phase is extracted twice with 300 ml of methylene chloride. The combined organic phases are washed three times with 200 ml of water until neutral, dried with sulphate
and concentrated in vacuo at
volume 120 ml. After crystallization by the addition of petroleum ether, 2-C (4-it-IQ xi-5-methyl-2-pyridyl) methyl sulphi-, 7-dihydro-5,5,7,7-tetramethylindo 3 is obtained. , 6-dlimidazole-6 (1H) -one with so pl. 205-207 ° C.
Example 11.14.8 5H-1,3-dioxolo 4,5-benzimidazole-6-thiol is weighed into 300 ml of alcohol and 17.0 g (76.5 mmol) of 2-chloromethyl-4-methoxy hydrochloride are added under ice-cooling. -3,5-dimethylpyridine. Then, a solution of 6.0 g of sodium hydroxide in the
14
Continue to move -10 ° C 2
150 ml of water, the mixture is heated to reflux overnight, followed by evaporation to dryness in vacuo. The residue is dissolved in 1000 methylene chloride. Washing solution - 500
First, bUU ml 1.5 and. sodium hydroxide solution, then three times with 500 ml of wobenzoic acid, sew the solution at -lU C z h, then pour the latter into a mixture of 300 ml of 2N. sodium carbonate solution and ice. The aqueous phase is extracted twice with 300 ml of methylene chloride. The combined organic phases are washed three times with 250 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at 35 ° C to a volume of 150 ml. After the addition of petroleum ether, crystallization gives 6- (4-methoxy-g (76.7 mmol) 15 3,5-dimethyl-2-pyridyl) methyl sulfinyl-5H-1, 3-dioxolo 4,5-f3 benzimide- angry, like 192-194 ° C.
Note er -13. 5.82 g (30.0 mmol) of 5H-1,3-dioxolo 4,5-f benzimidazole-6-thiol are weighed into 200 mp of alcohol and 7.1 g (30.1 mmol) of hydrochloride 2 are added with ice cooling - chloromethyl-4-ethoxy-3, 5-dimethylpyridine. Then, a solution of 2.4 g of sodium hydroxide in 100 ml of water is added dropwise, heated to reflux overnight and evaporated to dryness in vacuo. The residue is dissolved in 500 ml of methylene chloride. Rast20
ml
dyes, dried with sodium sulfate and the packer was first washed with 250 ml of 1.5N.
drew in a vacuum. The crude product is purified on 300 g of silica gel using ethyl acetate / methylene chloride (1: 1) as the solvent. After crystallization from methylene chloride / petroleum ether, 6- (4-methoxy-3,5-dimethyl-2-pyridsh1) methyl thio - 5H-1,3-dioxolo 4,5-f benzimide-, sol with t .pl. 178-179 ° C.
1.3 g of 6-j (4-methoxy-3, 5-dimethyl2-pyridyl) methyl-thio 1-5H-1,3-dioxolo 4,5-f J benzimidazole is dissolved in 25 ml of hot methanol and added are 40 ml of 5 n. solution of hydrogen chloride in acetic ether. After the ether has been added, 6- {(4-methoxy-3, 5-dimethyl-2-pyridyl) methyl thio-5H-1,3-dioxolo C4,5-f benzimidazole dihydrochloride crystallizes from mp. 20840
210 ° C.
EXAMPLE 12.3 13.3 g of 6- (4-methoxy-3, 5-dimethyl-2-pyridyl) methyl thio-5H-1,3-dioxolo 4,5-f 1 benzimidazole is dissolved in 300 ml of methylene chloride and chilled for a bath of ice / methanol to -10 ° C. Then, 7.5 g of trans- | crystallized from methylene chloride / petroleum ether of m-chlorinated sodium hydroxide solution and then three r for 300 ml of water, dried over sodium sulfate and evaporated in vacuo. The product product is 6 grams; ayut on 150 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluent. After crystallization from acetonitrile, 6- (4-ethoxy-3,5-dimesh1-2-pyridyl) methyl-Thio-5H-1,3-dioxole 4,5-fbenzimidazole with m.p. 184-185
Example 14. 7.4 g of 6-G (4 is xy-3,5-dimethyl-2-pyridyl) methyl thio. 5H-1,3-dioxolo 4,5-f benzimidazole is dissolved in 1000 ml methylene chloride and cooled to -30 ° C with dry ice / acetone. Then, 4.3 g of per-crystallized from methylene chloride / petroleum ether of m-chloroper benzoic acid is added over 10 minutes. The solution is kept stirring at -30 ° C for 45 minutes, then the latter is poured into a mixture of 10 m 2 N sodium carbonate solution and ice. The aqueous phase is extracted twice.
gg 400 ml methylene chloride. The combined organic phases are washed three times with 300 ml of water until neutral, dried with sodium sulphate and concentrated in vacuo at
50
14
Continue to move -10 ° C 2
-lU C z h, then ethylene is extracted into a mixture of 300 ml of sodium sodium and times. The compounds were washed three times with a neutral cossulfate of sodium Akum at 35 ° C after the addition of Chris 6- (4-methoxy-yl) methyl sulfide as a result.
sodium hydroxide solution and then three times with 300 ml of water, dried with sodium sulfate and evaporated in vacuo. The product product is 6 grams; ayut on 150 g of silica gel with ethyl acetate / methylene chloride (1: 1) as eluent. After crystallization from acetonitrile, 6- (4-ethoxy-3,5-dimesh1-2-pyridyl) methyl-Thio-5H-1,3-dioxolo 4,5-fllbenzimidazole with m.p. 184-185 c.
Example 14 7.4 g 6-G (4-ethoxy-3,5-dimethyl-2-pyridyl) methyl thio | -. 5H-1,3-dioxolo 4,5-f benzimidazole is dissolved in 1000 ml methylene chloride and cooled to -30 ° C with dry ice / acetone. Then, 4.3 g of m-chloroperobenzoic acid recrystallized from methylene chloride / petroleum ether are added over 10 minutes. The solution is continued to stir at -30 ° C for 45 minutes, then the latter is poured into a mixture of 10 ml 2 n. sodium carbonate solution and ice. The aqueous phase is extracted twice.
g 400 ml of methylene chloride. The combined organic phases are washed three times with 300 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at
0
151362402
35 C to a volume of 100 ml. After adding petroleum ether, crystallization occurs, resulting in 6- (4-ethoxy-3,5-dimethyl-2-pyridate 1) methyl-sulfinyl-5H-1,3-dioxolo 4,5-benzimidazole, m.p. 197-198 ° C.
Example 15. 5.82 g (30.0 mmol) of 5H-1,3-dioxolo l, 5-f benzimidazole 6-thiol is weighed into 200 ml of alcohol and added with ice cooling
6.3 g (30.3 mmol) of 2-chloromethyl-4-methoxy-5-methylpyridine hydrochloride. The solution is then added dropwise.
2.4 g of sodium hydroxide in 100 ml of water, the mixture is heated to reflux overnight and then evaporated to dryness in vacuo. The residue is dissolved in 500 ml of methylene chloride. The solution is washed first with 250 ml.
1.5n. sodium hydroxide solution, then three times with 300 ml of water, dried with sodium sulfate and evaporated to dryness in vacuo. The crude product is purified on
150 g of silica gel using ethyl acetate / methylene chloride (1: 1) as eluent. After crystallization from porous methylene / petroleum
6
790 mg of phosphorus trichloride are added and the mixture is heated to reflux for 16 hours. After cooling, the mixture is poured onto ice and sodium carbonate. The methylene chloride is removed, the organic phase is dried and the solvent is removed in a rotary evaporator. The 5,7-dihydro-2-chloro-5,5,7,7-tetramethylindeno 5,6-f imidazole-6 (1H) -one remaining as a residue is treated as a crude product.
To a solution of 470 mg of crude 2-chlor15 methyl-3-methyl-4-methoxypyridine,
dissolved in 50 ml of methylene chloride, 5 ml of triethylamine and 0.8 ml of thioacetic acid are added and the mixture is stirred overnight at room temperature. The solution is added onto ice and sodium carbonate. The methylene chloride is removed, the organic phase is dried and the solvent is removed. Remaining as residue
25 2-acetylthiomethyl-3-methyl-4-methoxy-pyridine is processed as a crude product.
20
To a solution of 500 mg of crude 2-acetylthiomesh1-3-methyl-4-methoxypyridine
the ester is obtained 6- ((4-methoxy-5-methyl-zo in 5 ml of methanol is added 5 ml of tri-2-pyridyl) methyl io) -5H-1,3-dioxoloethylamine and stirred in the continuation of 4, 5-f benzimidazole from m.p. 191-193 C. overnight at room temperature
Example 16. 4.3 g of 6- (4-metho- in nitrogen atmosphere. After removing xi-5-methyl-2-pyridyl) methyl thioC-5H-1,3-dioxolo 4,5-f, benzimidazal is dissolved in 100 ml of methylene chloride and cooled in a bath with ice / methanol to -10 ° C. Then 3.0 g of m-chloro-solvent recrystallized from methylene chloride / petroleum ether in a rotary evaporator is added to the crude 2-thiomethyl-3-methyl-4-methoxypyridine as a residue, which is processed directly.
To a solution of 500 mg of crude 5,7-di40 hydro-2-chloro-5,5,7,7-tetrametesh1-de-, 6-imidazole-6 (1H) -one and 330 mg of crude 2-thiomesh-3-metsh-4 -methoxypyridine in 50 ml of acetone is added 2.5 g of finely ground caperbenzoic acid carbonate. The solution is continued to stir at -10 C for 2 h, then it is drunk into a mixture of 100 ml 2 n. sodium carbonate solution and ice. The aqueous phase is extracted twice with 100 ml of methylene chloride. The combined organic phases are washed three times with 150 ml of water until neutral, dried with sodium sulfate and concentrated in vacuo at 35 ° C to a volume of 50 ml. After adding petroleum ether, 6- | (4-methoxy-5-methyl-2-pyridyl) methyl sulfinyl-5H-1,3-dioxolo crystallizes
40 hydro-2-chloro-5,5,7,7-tetrametesh1-de-, 6-imidazol-6 (1H) -one and 330 mg of crude 2-thiometsh-3-metsh-4-methoxy-pyridine in 50 ml of acetone added 2.5 g of finely ground carbonate K45 LIA are mixed and stirred for 18 hours at room temperature under argon atmosphere. After filtration and removal of the solvent, the residue is chromatographed on silica gel using chloride
50 methylene / ethyl acetate (10: 1), once medium pressure chromatography. After recrystallization from ethyl acetate / ether, 5,7-dihydro-2- (4-methoxy 4, 5-f benzimidazole is obtained, mp 182-184 ° C. gg H-methyl-2-pyridyl) methyl thio} -5,5,7,7. Example 17. To a solution of 500 mg of tetramethylindeno 5,6-f imidazole- (1.92 mmol) 5,7-dihydro-2-mercapto-6 (1H) -one with m.p. 218-220 C. 5,5,7,7-tetramethylindeno 5,6-imide-Analogously to examples 1-17, it is possible to sol-6 (1H) -one in 50 ml of 1,2-dichloroethane to emit the following compounds: , 7 di
6
790 mg of phosphorus trichloride are added and heated to temperature / reflux for 16 hours. After cooling, the mixture is poured onto ice and sodium carbonate. The methylene chloride is removed, the organic phase is dried and the solvent is removed in a rotary evaporator. The 5,7-dihydro-2-chloro-5,5,7,7-tetramethylindeno 5,6-f imidazole-6 (1H) -one remaining as a residue is treated as a crude product.
To a solution of 470 mg of crude 2-chlor5 methyl-3-methyl-4-methoxypyridine,
dissolved in 50 ml of methylene chloride, 5 ml of triethylamine and 0.8 ml of thioacetic acid are added and the mixture is stirred overnight at room temperature. The solution is added onto ice and sodium carbonate. Methylene chloride is removed, the organic phase is dried and the solvent is removed. Remaining as residue
5 2-acetylthiomethyl-3-methyl-4-methoxy-pyridine is processed as a crude product.
0
To a solution of 500 mg of crude 2-acetylthiomesh1-3-methyl-4-methoxypyridine
5 ml of triethylamine are added to 20 ml of methanol and stirred under prolonged nitrogen atmosphere. After removal
the solvent in a rotary evaporator is obtained as a residue a crude 2-thiomethyl-3-methyl-4-methoxypyridine, which is directly processed.
To a solution of 500 mg of crude 5,7-dihydro-2-chloro-5, 5,7,7-tetrametesh1-de, 6-imidazol-6 (1H) -one and 330 mg of raw 2-thiomesh-1-3-metsh-4- methoxypyridine in 50 ml of acetone was added 2.5 g of finely ground potassium carbonate and stirred for 18 hours at room temperature under argon atmosphere. After filtration and removal of the solvent, the residue is chromatographed on silica gel using chloride
methylene / ethyl acetate (10: 1), once chromatography with average chromatography. Recrystallization from ethyl acetate / ether gives 5,7-dihydro-2- (4-methoxy-3-methyl-2-pyridyl) methyl thio} -5,5,7,717
hydro-2- (4-methoxy-3-methyl-2-pyridyl) methyl thio-5,5,7,7 -tetramethylindo-J5,6-d imidazole-6 (1H) -one-oxime, t .pl. 160 ° C (decomposition), from the acetic esterJ 5,7-dihydro-2- .G (4-methoxy-3-metsh1-2-pyridyl) methyl-sulfinyl-5,5., 7, 7-tetramethylin- 5, - (- d Imidazol-6 (1H) -on-oxime, mp: 215-217 ° G, from methylene chloride) acetic ester; 5,7-dihydro-2-C (4-methoxy-3-metsh1-2-pyridyl) methyl thio1-5,5,7,7-tetramethylindo f5,6-dj imidazole-6 (1H) -one-0-methyl-oxime, so pl. 100 ° C, from n-hexane / / ether; 5, 7-dihydro-2- (4-methoxy-3-metsh1) -2-pyridyl) methyl 1-sulfinyl1.5,5,7,7-tetramethylindeno 5,6 -d3 imidazole-6 (1H) -one-0-methyloxime, so pl. 140 ° C (decomposition), from ether; 5,7-dihydro-2- {(4-methoxy-3,5-dimethyl-2-pyridyl) metsh1-thio-5,5,7,7-tetramethylindo 5,6-d imidazole-6 (1H) -on- oxime, so pl. 233-235 ° C, from acetic ester; 5-7-dihydro-2- (methoxy-3,5-dimethyl-2-pyridyl) methyl | - sulfinyl1-5,5,7,7-tetramethylindeno 5,6-djimidazole-6 (1H) -one-oxime, mp 215-217 ° G, from methipenchloride / petroleum ether; 5,7-dihydro-2- (i-methoxy-3,5-dimethyl-2-pyridsh1) mets {1 - thioT | -5,5,7,7-tetramethylindeno 5,6-d imidazole-6 (1H) -one-0-methyloxime, mp, 110-112 C, from acetone / water; 5,7-di-hydro-2- (4-methoxy-3,5-dimethyl-2-pyridyl) -alkyl sulfinyl-5,5,7,7-tetramethylindeno 5,6-d3 imidazol-6 (1H) -one -0-methyloxime, so pl. 173-175 ° C, from methylene chloride / petroleum ether. .
The following experiment was carried out to determine the action against formation.
For each dose of the test substance, groups of male rats (8 rats each time) weighing 130-150 g are used. Prior to the experiment, animals do not receive food during the day, but receive water as desired. Different doses of the tested substances (suspended in 0.5% but 1 tragacanth) or vehicle (in control animals) were administered twice through the mouth; 1 hour before administration of 20 mg / kg of indomethacin through the mouth and 2 hours after that. In control animals, the dose of indomethacin, administered in the course of 5 hours, damages the stomach. 6 h after the first injection of the test substance (or only

40218
tel) animals are killed. Count the rats, which can not detect macroscopic damage to the gastric mucosa. By ED is the dose of the test substance at which 50% of the animals are protected from damage. I
The following experiment was carried out to determine the lowering level of gastric acid.
In Beagle dogs (males and females), part of the fundus of the stomach is separated from the rest of the stomach in the form of a carnatum. A steel cannula is inserted into the pocket, drawn through the abdomen outwards. Before the experiment for 18 h, the animals do not receive food, BUT receive water at will; During the experiment, animals in a wakeful state and in a standing position, the release of gastric acid is stimulated by intravenous infusion of 4-methylhistamine, a selective histamine receptor agonist
25
thirty
35
H. The secretion of gastric acid is determined on the secretion of the gastric pocket at intervals of 15 minutes. As soon as the secretion of gastric acid reaches a constant value, the test substances are administered through the mouth in the form of dry powders in gelatin capsules. A series of HP indicates such a dose of the test substance, which in treated animals causes a 50% inhibition of gastric acid release caused by 4-methylhistamine in treated animals.
In tab. 1 shows the test results (DL in the case of once 40
oral administration in mice) of the compounds: A - 5,7-dihydro-2- {(4-methoxy-3,5-dimethyl-2-pyridyl) methyl - 5,5,7,7-tetramethylindeno imidazole-6 ( 1 H) -one ;. B - 5,7-dihydro-2 45 C (-methoxy-3,5-dimethyl-2-pyridsh1) methyl-sulfinyl-5,5,7,7-tetramethylindo 5, 6-d imidazole-6 (1H) - he; B - 5,7-dihydro-2- (4-methoxy-3-methyl-2-pyridyl) methyl thio-5,5,7,7-tetra 50 methyl indo 5,6-d imidazole-6 (1H) -one; G - 5,7-dihydro-2 - {(4-methoxy-3-methyl-2-pyridyl) methyl sulfinyl-5,5,7, 7-tetramethylindeno 5,6-d imidazol-6 (1H) - he; D - 6- (4-methoxy-3-metip55 2-pyridyl) methyl sulfinyl-5H-1, 3-dioxylo 4,5-benzimidazole; E - 6- {(4-methoxy-3, 5-dimethyl-2-pyridyl) methyl sulfinyl-5H-1,3-dioxolo 4,5-Zbenzimidazole; J - 2- (4-eto19 .1
si-3-methyl-2-pyridyl) methyl} thio-5,7-dihydro-5,5,7, 7-tetramethylindeno C5,6-yZimidazole-6 (1H) -one; 3 - 5,7-dihydro-2- ((4-methoxy-3-methyl-2-pyridyl) methyl sulfinyl-5,5,7,7-tetramethylindeno 5,6-d imidazol-6 (1H) -one- 0-methyloxime; AND - 5,7-di-hydro-2- (.4-methoxy-3-methyl-2-pyridyl) methyl-thio-5,5,7, 7-tetramethylindeno 5, 6 -dJimidazole-6 (1H) -on-0-methyloxime.
Table 1
The proposed compounds can be used as active principles for the preparation of hard gelatin capsules, the contents of which have
Active principle Milk sugar
(powdered) milk sugar
(crystalline) corn starch
white
Talc
Magnesium stearate
ten
6240220
Content weight of capsule is 250.0 mg.
The active principle and auxiliary agents are mixed and the mixture is fed into hard gelatin capsules of suitable size. If necessary, the capsules are then coated with a varnish resistant to the action of gastric juice, consisting of oxypropylmethylcellulose phthalate.
B tab. 2 shows the results of comparative tests of compounds A, B, C, D, D, E, F, 3, I, as well as compounds 5 of the research institutes: K - 5,7-dihydro-5,5,7,7-tetramethyl- 2- (2-pyridylmethyl) tsG-indeno 5,6-d Iimazol-6 (1H) -on; L - 5,7-dihydro-5,5,7,7-tetrametesh1-2- {(5-methyl-2-pyridine) methyl thio-indeno {5,6-d imidazole-6 (1H) -one; M - 5,7-dihydro-5,5,7,7-tetrametsh1-2-C (2-pyridylmethyl) sulfinyl-indeno 5,6-d imidazole-6 (1H) -one; H - 6- (5-methyl-2-. Pyrndyl-methyl) thgH-5H-1,3-dioxolo
25 p 5-G1-benzimidapaz; O - 6- {t (5-methyl-2-pyridyl) methyl sulfinyl-5H-1,3-dioxolo-4,5-benzimidazole; P - 5-trifluoromethyl-1-2- (4-methoxy-3, 5-dimesh-1 -2-pyridyl) methyl (1H) -benzimidazole; P - 5-trifluoromethyl-2-C (4-methoxy-2-Shfidil) metsulfinyl - (1H) -benzimidazole.
T a b ±. and c a 2
20
45
50
55
21..1362402
Continuation of table 2
22
 R
-rp
V b b
ORe ti "6
I OR-C-C-C 5 R7RS 7
where R, Ry, Rg and R are each lower
alkyl;
Rg is hydrogen or
lower alkyl,
or salts thereof with acids, characterized in that the compound of the general formula
TO

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining imidazole derivatives of the general formula
 C0) iv RI-XK -S-CH,
n
where one of RJ and RJ is lower alkyl, and the other is hydrogen;
RJ is lower alkyl;
n 0 or 1;
A is a residue of the formula —O — CHg —O;
Compiled by G.Zhukova Editor O.Yurkovetska Tehred M.DIDIK Proofreader A.T.
Order 6306/59 Circulation 372 Subscription VNIIPI USSR State Committee
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
Production and printing company, Uzhgorod, Projecto st., 4
where A has the indicated meanings;
Y has the following values, is reacted with a compound of the general formula
Ri ORG Y-CH5- Rv
thirty
where R, R and R ,, have the specified value i.
neither;
Y and Y is one mercaceto group,
and the other is halogen,
and select the desired product, where, 35 or is oxidized and allocate the desired product, where, in free form or as a salt, with an acid.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US4180662A|1979-12-25|Thiazine derivatives

---

US5703097A|1997-12-30|5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives

---

US4248880A|1981-02-03|Treatment of gastric ulcers with naphthimidazole derivatives

---

US4782055A|1988-11-01|Imidazopyridine compounds useful in the treatment of ulcers

---

IL81609A|1994-10-21|2-| thienoimidazole derivatives and analogs, a process for their preparation, pharmaceutical compositions containing them and their use as inhibitors of gastric acid secretion

---

JPH1087629A|1998-04-07|New isoquinoline derivative, and its medicinal use

---

EP0115469B1|1987-05-20|Pyrazolo|pyridin-3-ones condensed with a heterocycle

---

SU1232145A3|1986-05-15|Method of producing pyrimidine derivatives or pharmaceutically acceptable salts thereof

---

US4224445A|1980-09-23|Thienothiazine derivatives

---

WO1993016076A1|1993-08-19|3-|-4h^_-pyrido[1,2-a^_]pyrimidine-4-ones, pharmaceutical compositions containing the same and the preparation thereof

---

SU1362402A3|1987-12-23|Method of obtaining derivatives of imidazole or their salts with acids

---

KR0142815B1|1998-07-15|Novel 5-pyrrolyl-o-halogeno-2-pyridyl methylsulfinylbenzimidazole derivatlves

---

IE58587B1|1993-10-06|Benzimidazoles

---

US4766133A|1988-08-23|-pyridinium compounds

---

EP0008652B1|1982-09-22|New intermediates and their use for the preparation of new oxadiazolo-pyrimidine derivatives

---

US4127574A|1978-11-28|4-Hydroxy-3-sulfonyl-quinolin-2|-ones

---

US4150132A|1979-04-17|Oxadiazolopyrimidine derivatives

---

US4950677A|1990-08-21|Benzimidazole derivative compounds and method of making

---

EP0354788A1|1990-02-14|Novel imidazole derivatives

---

US5037830A|1991-08-06|Novel thiouracyl derivatives, pharmaceutical compositions containing them and process for preparing same

---

US4187303A|1980-02-05|Thiazine derivatives

---

US3887570A|1975-06-03|Derivatives of pyrazolo|thieno|pyridine-2-carboxylic acids

---

US4090020A|1978-05-16|Thienothiazine derivatives

---

KR880001636B1|1988-09-03|Process for the preparation of oxadiazolopyrimidine derivatives

---

US4021554A|1977-05-03|1,4-Oxathiino[2,3-c]pyrrole derivatives

同族专利:

---

公开号 | 公开日

---

ES8706128A1|1987-06-01|

---

ES551472A0|1987-06-01|

---

PT80315A|1985-05-01|

---

NZ211773A|1989-01-06|

---

ES551471A0|1987-06-01|

---

EP0163842A1|1985-12-11|

---

NO162617C|1990-01-24|

---

AU589555B2|1989-10-19|

---

SU1396965A3|1988-05-15|

---

DD232277A5|1986-01-22|

---

CS250248B2|1987-04-16|

---

NO162617B|1989-10-16|

---

IL74880D0|1985-07-31|

---

ZW4585A1|1985-11-20|

---

AU4122885A|1985-10-24|

---

NO851550L|1985-10-21|

---

KR850007256A|1985-12-02|

---

CS250249B2|1987-04-16|

---

US4981861A|1991-01-01|

---

ES551473A0|1987-06-01|

---

JPS60233070A|1985-11-19|

---

ES8706129A1|1987-06-01|

---

FI851431A0|1985-04-10|

---

US4634710A|1987-01-06|

---

ES8706124A1|1987-06-01|

---

DK148585D0|1985-04-01|

---

IL74880A|1988-06-30|

---

ES8607963A1|1986-06-16|

---

PH21046A|1987-07-03|

---

GR850949B|1985-11-25|

---

HUT37613A|1986-01-23|

---

HU193362B|1987-09-28|

---

PT80315B|1987-03-16|

---

MC1650A1|1986-04-07|

---

FI851431L|1985-10-20|

---

ZA852765B|1985-11-27|

---

ES542370A0|1986-06-16|

---

DK148585A|1985-10-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE1805548A1|1968-10-26|1970-10-08|Agfa Gevaert Ag|Benzimidazole derivatives and their photographic uses|

---

IN148930B|1977-09-19|1981-07-25|Hoffmann La Roche|

---

SE7804231L|1978-04-14|1979-10-15|Haessle Ab|Gastric acid secretion|

---

CH644116A5|1980-08-21|1984-07-13|Hoffmann La Roche|IMIDAZOLE DERIVATIVES.|

---

US4472409A|1981-11-05|1984-09-18|Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung|2-Pyridylmethyl thiobenzimidazoles with gastric acid secretion inhibiting effects|

---

SE8300736D0|1983-02-11|1983-02-11|Haessle Ab|NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS|

---

IL71664A|1983-05-03|1987-11-30|Byk Gulden Lomberg Chem Fab|Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same|

---

HU191757B|1983-05-03|1987-04-28|Byk Gulden Lomberg Chem Fab|Process for producing new tricyclic ethers|

---

IL75400A|1984-06-16|1988-10-31|Byk Gulden Lomberg Chem Fab|Dialkoxypyridine methylbenzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same|DK337086A|1985-08-12|1987-02-13|Hoffmann La Roche|benzimidazole|

---

US6749864B2|1986-02-13|2004-06-15|Takeda Chemical Industries, Ltd.|Stabilized pharmaceutical composition|

---

US5433959A|1986-02-13|1995-07-18|Takeda Chemical Industries, Ltd.|Stabilized pharmaceutical composition|

---

SE9002043D0|1990-06-07|1990-06-07|Astra Ab|IMPROVED METHOD FOR SYNTHESIS|

---

US6852739B1|1999-02-26|2005-02-08|Nitromed Inc.|Methods using proton pump inhibitors and nitric oxide donors|

---

CA2493618A1|2002-08-01|2004-02-12|Nitromed, Inc.|Nitrosated proton pump inhibitors, compositions and methods of use|

---

RU2487126C1|2011-11-28|2013-07-10|Открытое акционерное общество "Федеральный научно-производственный центр "Алтай"|Method of producing 1,4-dioxane-2,3-diol|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

CH196684|1984-04-19|

---